A UK biotech company exploring new ways of treating Alzheimer’s and other neurodegenerative diseases has raised £48mn ($61mn) in its first big funding round.
Although AstronauTx does not expect any of its drugs to reach clinics for at least three or four years, the financing is a step towards helping millions of sufferers.
您已阅读12%（463字），剩余88%（3247字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。